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Background:  We performed a retrospective longitudinal study on the effects of changes in weight, body composition, and ho-
meostasis model assessment (HOMA) indices on glycemic progression in subjects without diabetes during a four-year follow-up 
period in a community cohort without intentional intervention. 
Methods:  From 28,440 non-diabetic subjects who participated in a medical check-up program in 2004, data on anthropometric 
and metabolic parameters were obtained after four years in 2008. Body composition analyses were performed with a bioelectri-
cal impedance analyzer. Skeletal muscle index (SMI, %) was calculated with lean mass/weight×100. Subjects were divided into 
three groups according to weight change status in four years: weight loss (≤-5.0%), stable weight (-5.0 to 5.0%), weight gain (≥ 
5.0%). Progressors were defined as the subjects who progressed to impaired fasting glucose or diabetes. 
Results:  Progressors showed worse baseline metabolic profiles compared with non-progressors. In logistic regression analyses, 
the increase in changes of HOMA-insulin resistance (HOMA-IR) in four years presented higher odds ratios for glycemic pro-
gression compared with other changes during that period. Among the components of body composition, a change in waist-hip 
ratio was the strongest predictor, and SMI change in four years was a significant negative predictor for glycemic progression. Chang-
es in HOMA β-cell function in four years was a negative predictor for glycemic progression. 
Conclusion:  Increased interval changes in HOMA-IR, weight gain and waist-hip ratio was associated with glycemic progression 
during a four-year period without intentional intervention in non-diabetic Korean subjects. 
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INTRODUCTION
Weight change is one of the most important markers that 
strongly reflects the effectiveness of interventions on lifestyle 
changes in prevention of type 2 diabetes. In the lifestyle inter-
vention group of the Diabetes Prevention Program, weight 
loss was the dominant predictor of reduced diabetes risk, with 
a 16% reduction observed for every kilogram of weight loss 
during 3.2-year follow-up [1]. In addition to weight loss, chang-
es in body composition may influence diabetes risk [2]. With 
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regard to body-fat distribution, lifestyle interventions have led 
to a reduced diabetes risk, in parallel with reductions preferen-
tially in visceral fat as well as subcutaneous fat and total body 
fat [3]. Furthermore, few studies report the association of skel-
etal muscle loss with glycemic status [4,5]. 
  Homeostasis model assessment-insulin resistance (HOMA-
IR) is frequently used as a marker for insulin sensitivity, and 
HOMA β-cell function is the index of insulin secretory func-
tion derived from fasting plasma glucose and insulin concen-
trations [6,7]. Although the predictability of these markers for 
future development of type 2 diabetes was suggested in previ-
ous studies [8-11], few studies were performed in non-diabet-
ic subjects examining their role as the predictor for future gly-
cemic progression.
  Although there are studies reporting the effects of weight 
change, body composition, and insulin function on the future 
development of diabetes, most of the previous studies results 
are from the intervention studies, and have not examined what 
occurs in response to natural changes in weight status. Further-
more, there are some studies suggesting that purposeful weight 
loss may not be beneficial and may even be detrimental in pa-
tients with cardiovascular diseases [12,13]. Although we know 
that weight loss affects the progression of diabetes, we do not 
have a clear answer as to how the weight change would affect 
the body composition and insulin function, and prevent gly-
cemic progression in subjects without diabetes.
  We hypothesized that weight increases would have a posi-
tive correlation with glycemic progression, and that increase 
in fat mass and decrease in muscle mass would affect glycemic 
progression. Furthermore, insulin resistance and decreased 
insulin secretory function assessed by HOMA indices would 
have deleterious effects on glycemic progression. Therefore, 
we designed a prospective study to observe the changes in 
weight, body composition and HOMA indices during a four 
year period, and analyzed how the interval changes in these 
parameters affected glycemic progression in association with 
weight change in Korean subjects without diabetes.
METHODS
Study population 
We designed a retrospective longitudinal study to investigate 
the role of baseline and changes in body weight and compo-
nents of body composition on glycemic progression during a 
four-year follow-up period in participants in a medical health 
checkup program in the Health Promotion Center at Kangbuk 
Samsung Hospital, Sungkyunkwan University, Seoul, Korea. 
The purpose of the medical health checkup program is to pro-
mote health of the employees through regular health checkups 
and early detection of existing diseases, if any. Most of the ex-
aminees are the employees of various industrial companies 
around the country and their family members. The cost of the 
medical examinations of the employees and their family mem-
bers are largely paid by their employers, and a considerable 
proportion of the examinees repeat the exam annually or bi-
annually. We took advantage of this opportunity to conduct a 
follow-up study.
  Among 30,108 subjects who participated in the medical 
checkup program in 2004, we excluded subjects who had a 
self-reported history of diabetes or fasting blood glucose level 
≥126 mg/dL (n=645), history of malignancy (n=126), heart 
disease (n=112), cerebrovascular disease (n=22), abnormal 
serum free T4 concentration (n=176) or who had missing 
data for the analyses (n=1,150). These specific exclusions re-
sulted in the final study population of 28,440 subjects (mean 
age, 39 years; range, 19 to 86 years) who were selected for the 
follow-up study after four years (Fig. 1). Ethics approval for 
study protocol and analysis of the data was obtained from the 
Institutional Review Board of Kangbuk Samsung Hospital.
  At baseline, all subjects were divided into two groups by fast-
ing blood glucose, normoglycemia (<100 mg/dL) and impaired 
Fig. 1. Selection of study participants.
30,108 Apparently healthy  
subjects screened in 2004
28,440 Diabetes-free cohort in 2004
3,756 subjects (13.2%) with glycemic progression,
432 subjects (1.5%) with diabetes development in 2008
1,668 Exclusion criteria in 2004
645 Diabetes history or FBS ≥ 126 mg/dL  
126 History of malignancy
112 History of heart disease
22 History of cerebrovascular disease
176 Abnormal serum Free T4 concentration
1,150 Missing data
Followed up for 4 years140
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fasting glucose (IFG; ≥100 mg/dL). After four years, develop-
ment of diabetes was defined by fasting blood glucose ≥126 
mg/dL or self-reported diagnosis of diabetes. Glucose progres-
sion was defined by the following criteria: converted from 
normoglycemia to IFG, from normoglycemia to diabetes 
(≥126 mg/dL) or from IFG to diabetes after four years (pro-
gressor).
Laboratory measurements 
Height, weight, systolic and diastolic blood pressures were 
measured in duplicate and the results were averaged. The blood 
pressures were taken with a standardized sphygmomanometer 
after at least 5 minutes of rest, according to the Hypertension 
Detection and Follow-up Program protocol [14]. The body 
mass index (BMI) was calculated by dividing the weight (kg) 
by the height (m) squared. 
  After 12 hours of fasting, fasting blood glucose, total choles-
terol, triglyceride, high density lipoprotein cholesterol (HDL-
C), and low density lipoprotein cholesterol (LDL-C) levels were 
checked. The hexokinase method (Advia 1650 Autoanalyzer; 
Bayer Diagnostics, Leverkusen, Germany) was used to mea-
sure blood glucose levels and an enzymatic colorimetric test 
was used to measure total cholesterol and triglyceride levels. 
The selective inhibition method was used to measure the level 
of HDL-C and a homogeneous enzymatic calorimetric test 
was used to measure the level of LDL-C. Serum insulin con-
centration was measured with an immunoradiometric assay 
(INS-IRMA; Biosource, Nivelles, Belgium), with intra- and in-
ter-assay coefficients of variation of 1.6 to 2.2% and 6.1 to 6.5%, 
respectively. 
  Percent weight change (%) was calculated by the change in 
weight in four years of follow-up divided by baseline weight in 
2004. Subjects were divided into three groups according to the 
percent weight change from baseline; weight loss group (≤ 
-5.0%), stable weight group (-5.0 to 5.0%), weight gain (≥5.0%). 
Body composition analyses by bioelectrical impedance 
analyses (BIAs)
Body composition measurements of the subjects were carried 
out by segmental bioelectric impedance, using eight tractile 
electrodes according to the manufacturer’s instructions (In-
Body 3.0; Biospace, Seoul, Korea). Lean mass (kg), fat mass 
(kg), percent fat mass (%) and waist-hip ratio (WHR), as a 
marker of abdominal obesity, were measured. As muscle mass 
is strongly correlated with weight, the effect of weight was ad-
justed with the calculation of skeletal muscle mass (SMI, %) 
using the following formula [15]: SMI=lean mass/weight×100.
Assessment of insulin resistance and insulin secretion by 
homeostasis model assessment (HOMA) indices
HOMA-IR and HOMA β-cell were calculated according the 
following formula [6]: 
HOMA-IR=fasting insulin (μU/mL)×fasting glucose 
(mmol/L)/22.5
HOMA β-cell function=20×fasting insulin (μU/mL)/fast-
ing glucose (mmol/L)–3.5
Statistical analysis
Data are expressed as the number or proportion of the subjects 
(%) and means with standard deviation. To see the differences 
in metabolic parameters at baseline between those who pro-
gressed or did not progress, baseline parameters were com-
pared between the progressor and non-progressor with Stu-
dent’s t-test. To see how the changes in weight would affect 
metabolic parameters in four years, mean values of parameters 
were compared in three groups divided according to weight 
change status at baseline and after four years by a one-way 
ANOVA test. To compare the effects of interval changes of 
each parameter on glycemic progression, logistic regression 
analyses by backward method were performed with glycemic 
progression to analyze the effects of interval changes in vari-
ous body composition components and HOMA indices on 
glycemic progression in four years. The proportions of pro-
gressors were compared according to the tertiles groups of in-
terval changes in each parameter with a chi-square test. A P 
value <0.05 was considered as statistically significant. Statisti-
cal analyses were performed using the SPSS version 17.0 (SPSS 
Inc., Chicago, IL, USA).
 
RESULTS 
The clinical characteristics of the participants at baseline 
and after four years
Baseline characteristics of the participants are presented in Ta-
ble 1. All baseline parameters were metabolically worse in 
progressors compared with non-progressors, except for SMI 
(Table 1). Although the baseline mean values for SMI were not 
significantly different between the two groups, progressors ex-
hibited a significantly greater decline in SMI compared with 
non-progressors (P<0.01). Progressors displayed a significant-141
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ly higher baseline HOMA-IR and a lower baseline HOMA 
β-cell function compared with non-progressors (Table 1). In 
addition, progressors had a significantly greater increase in 
HOMA-IR and greater decrease in HOMA β-cell function 
during the four-year follow-up compared with non-progres-
sors (Table 1).
  At baseline in 2004, 6,991 subjects (24.6%) had IFG and af-
ter four years, 7,167 subjects (25.2%) had IFG, and 432 subjects 
(1.5%) developed diabetes mellitus. Regarding glycemic pro-
gression, in four years, 3,756 subjects (13.2%) progressed to a 
worse glucose tolerant status, that is, from normoglycemia to 
IFG, from IFG to diabetes or normoglycemia to diabetes.  
Comparisons of the baseline mean values of parameters 
according to the three groups of weight change status 
during the four-year follow-up
When the participants were divided into three groups accord-
ing to weight change status after four years, subjects in the 
weight gain group were the youngest and displayed the lowest 
BMI, therefore all the parameters were metabolically better 
than the subjects in the stable weight and weight loss groups 
(Table 2). However, after four years, although the weight gain 
group was the youngest group, all of the metabolic parameters 
worsened compared with the weight loss and stable weight 
groups (Table 2). 
Table 1. Baseline characteristics of the participants according to glycemic progression status over 4 years
All (n=28,440) Progressor (n=3,756) Non-progressor (n=24,684) P value
Age, yr  38.8±6.6 39.8±6.8  38.7±6.5  <0.01
Sex:male, n (%) 19,392 (68.2) 3,034 (80.8) 16,358 (66.3) <0.01
Weight, kg  66.9±11.4 70.6±11.0  66.4±11.4  <0.01
BMI, kg/m
2  23.6±2.9 24.6±3.0  23.5±2.9  <0.01
FBG, mg/dL  94.2±8.5 95.8±7.7  93.9±8.6  <0.01
Total cholesterol, mg/dL  189.8±32.7 195.3±33.3  189.0±32.5  <0.01
Triglyceride, mg/dL  131.0±82.4 153.4±93.4  127.5±80.1  <0.01
HDL-C, mg/dL  57.4±10.9 56.3±10.4  57.5±11.0  <0.01
LDL-C, mg/dL  115.8±28.8 120.0±29.4  115.2±28.7  <0.01
SBP, mm Hg  115.5±13.1 118.5±14.0  115.0±12.9  <0.01
DBP, mm Hg  75.5±10.0 78.0±10.3  75.1±9.9  <0.01
Percent body fat, % 23.6±5.5 23.8±5.3  23.6±5.5  0.029
Lean mass, kg  48.3±8.7 50.8±8.1  47.9±8.7  <0.01
SMI, %  72.2±5.5 72.0±5.3  72.2±5.5  0.112
Waist-hip ratio  0.862±0.05 0.88±0.05  0.86±0.05  <0.01
Mean weight change in 4 years, kg 0.52±3.3 1.0±3.5 0.45±3.3 <0.01
Mean percent weight change, % 0.898±4.9 1.53±5.0 0.80±4.9 <0.01
Change in percent body fat, %  0.15±3.0 0.48±2.8  0.10±3.0  <0.01
Change in lean mass, kg  0.28±2.19 0.41±2.1  0.26±2.2  <0.01
Change in SMI, % -0.18±3.4 -0.47±2.9 -0.14±3.5 <0.01
Change in waist-hip ratio  0.010±0.03 0.012±0.03  0.009±0.03  <0.01
HOMA-IR  2.21±0.83 2.30±0.87 2.19±0.83 <0.01
HOMA β 116.6±60.5 109.8±50.5 117.6±61.8 <0.01
Change in HOMA-IR -0.34±0.99 0.23±1.14 -0.44±0.93 <0.01
Change in HOMA β -23.3±77.7 -32.5±47.6 -21.9±81.2 <0.01
Values are presented as means±standard deviation or numbers (percent). 
BMI, body mass index; FBG, fasting blood glucose; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; SMI, skeletal muscle index; HOMA, homeostasis model assessment; IR, insulin re-
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  Although the baseline HOMA-IR value was the lowest in 
weight gain group, after four years, the weight gain group dem-
onstrated the highest HOMA-IR value among the three groups, 
and the weight loss group significantly demonstrated the low-
est HOMA-IR value compared with the other two groups (Ta-
ble 2). For HOMA β-cell function, although the weight gain 
Table 2. Comparisons of the baseline mean values of parameters according to the 3 groups of weight change status during 4 years 
of follow-up
Weight loss group 
(≤-5.0%) 
Stable weight group 
(-5.0 to 5.0%) 
Weight gain group 
(≥5.0%) 
Post-hoc analyses  P value 
Mean values in 2004
No. (%) 2,705 (9.5)  20,790 (73.1) 4,945 (17.4)
Age, yr 39.7±7.5  39.2±6.6  36.7±5.4  I≠II, I≠III, II≠III <0.01 
BMI, kg/m
2  24.8±3.0  23.7±2.9  22.7±2.8  I≠II, I≠III, II≠III <0.01 
FBG, mg/dL  95.0±9.4  94.2±8.5  93.5±7.9  I≠II, I≠III, II≠III <0.01 
TC, mg/dL  195.2±33.0  190.6±32.9  183.5±30.9  I≠II, I≠III, II≠III <0.01 
TG, mg/dL  142.5±94.5  133.8±83.9  112.6±64.1  I≠II, I≠III, II≠III <0.01 
HDL-C, mg/dL  57.5±11.5  57.1±10.8  58.1±11.1  II≠III <0.01
LDL-C, mg/dL  119.3±29.2  116.4±28.9  111.5±27.7  I≠II, I≠III, II≠III <0.01 
SBP, mm Hg  117.2±14.0  115.6±13.1  113.7±12.8  I≠II, I≠III, II≠III <0.01 
DBP, mm Hg  76.4±10.5  75.8±10.0  74.0±9.7.0  I≠II, I≠III, II≠III <0.01 
Lean mass, kg  48.2±9.1  48.6±8.7  47.1±8.4  I≠III, II≠III <0.01 
SMI, % 69.6±5.3 72.2±5.4 73.5±5.7 I≠II, I≠III, II≠III <0.01
Percent body fat, %  26.3±5.6  23.6±5.3  22.2±5.8  I≠II, I≠III, II≠III <0.01 
Waist-hip ratio  0.880±0.05  0.864±0.05  0.846±0.05  I≠II, I≠III, II≠III <0.01 
HOMA-IR 2.42±1.0 2.21±0.82 2.07±0.76 I≠II, I≠III, II≠III <0.01
HOMA β 123.7±57.9 116.3±56.9 113.5±74.8 I≠II, I≠III, II≠III <0.01
Mean values in after 4 years
BMI, kg/m
2  22.8±2.7 23.8±2.9 24.5±3.1 I≠II, I≠III, II≠III <0.01
FBG, mg/dL  95.0±16.5 95.3±10.5 95.8±9.7 I≠III, II≠III <0.01
TC, mg/dL  190.8±32.5 197.2±33.2 198.9±33.6 I≠II, I≠III, II≠III <0.01
TG, mg/dL  106.5±67.6 133.9±84.8 141.4±88.8 I≠II, I≠III, II≠III <0.01
HDL-C, mg/dL  57.9±13.8 54.1±12.4 53.2±11.7 I≠II, I≠III, II≠III <0.01
LDL-C, mg/dL  105.9±28.1 112.6±29.1 114.5±29.3 I≠II, I≠III, II≠III <0.01
SBP, mm Hg  112.3±14.2 114.6±13.5 114.4±13.3 I≠II, I≠III <0.01
DBP, mm Hg  72.8±9.9 74.3±9.7 73.9±9.8 I≠II, I≠III, II≠III <0.01
Lean mass, kg  46.3±8.8 48.7±8.9 49.0±8.9 I≠II, I≠III <0.01
SMI, % 72.8±5.6 72.2±5.6 70.8±5.9 I≠II, I≠III, II≠III <0.01
Percent body fat, %  22.8±5.8 23.5±5.6 25.0±6.1 I≠II, I≠III, II≠III <0.01
Waist-hip ratio  0.860±0.04 0.872±0.05 0.877±0.05 I≠II, I≠III, II≠III <0.01
HOMA-IR 1.74±0.96 1.86±0.98 1.90±1.14 I≠II, I≠III <0.01
HOMA β 91.7±74.9  94.1±71.2 90.7±56.6 II≠III 0.004
Values are presented as means±standard deviation or numbers (percent). 
BMI, body mass index; FBG, fasting blood glucose; TC, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-
C, low density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; SMI, skeletal muscle index; HOMA, homeo-
stasis model assessment; IR, insulin resistance. 143
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group presented the lowest HOMA β-cell function at baseline, 
after four years, the weight gain group exhibited the lowest 
value and the stable weight group exhibited the highest value 
for HOMA β cell function (Table 2). 
Determinants of glycemic progression after adjustment for 
multiple metabolic parameters, including weight change, 
body composition, and HOMA indices
When logistic regression analyses were performed with glyce-
mic progression as the dependent variable, the odds ratio (OR) 
for glycemic progression increased 1.389 and 2.29 times in the 
stable weight and weight gain groups, respectively, compared 
with the weight loss group after adjustment for confounding 
variables (Table 3). When changes in HOMA indices were in-
cluded in the model, the increment in the OR for glycemic 
progression observed in the stable weight and weight gain 
groups was attenuated to 1.203 and 1.765, respectively. In ad-
dition, changes in HOMA β-cell function produced a negative 
correlation with glycemic progression, and changes in HOMA-
IR significantly produced a positive correlation with glycemic 
progression, with an OR of 3.153 and 10.468 in 2nd and 3rd 
tertile groups of changes in HOMA-IR compared with the 1st 
tertile group (Table 3). 
  When changes in components of body composition were 
included in the model, changes in WHR showed the most sig-
nificant association with glycemic progression, and the high-
est tertile for WHR change exhibited a 1.29-fold increased risk 
for glycemic progression compared with the lowest tertile (Ta-
ble 4). When changes in HOMA indices were included in the 
model, changes in HOMA-IR produced the highest OR for 
glycemic progression after adjustment for other body compo-
sition components with an OR of 10.295 in the highest tertile 
of HOMA-IR compared with the lowest tertile (Table 4). 
Comparisons of the proportion of progressors according to 
the interval changes in multiple components during the 
four-year follow-up
  When the proportion of progressors was compared accord-
ing to the interval changes in individual components, the pro-
portion of progressors increased as the tertiles of weight change 
status increased from the weight loss to the weight gain groups 
(Fig. 2). The proportion of progressors significantly increased 
as the tertiles of changes of percent body fat and WHR in-
creased from the 1st to 3rd tertiles, and as the tertiles of chang-
Table 3. Multivariate logistic regression analyses with glyce-
mic progression as the dependent variable with weight change 
and HOMA indices in the model
OR 95% CI
Model 1
a
Weight change ≤-5.0% 1 (reference) -
-5.0<Weight change<5.0%  1.389 1.216 to 1.587
Weight change≥5.0%  2.290 1.969 to 2.663
Model 2
a
Weight change≤-5.0% 1 (reference) -
-5.0<Weight change<5.0%  1.203 1.046 to 1.384
Weight change≥5.0%  1.765 1.505 to 2.069
Change in HOMA β 0.987 0.987 to 0.988
Change in HOMA-IR 1st tertile 1 (reference) -
Change in HOMA-IR 2nd tertile 3.153 2.814 to 3.534
Change in HOMA-IR 3rd tertile 10.468 9.252 to 11.843
HOMA, homeostasis model assessment; OR, odds ratio; CI, confi-
dence interval; IR, insulin resistance.
aAdjusted for age, gender, fasting blood glucose, triglyceride, total 
cholesterol, systolic blood pressure and baseline weight.
Table 4. Multivariate logistic regression analyses with glyce-
mic progression as the dependent variable with components 
of body composition and HOMA indices in the model
OR 95% CI
Model 1
a
Change in skeletal muscle index 0.977 0.929 to 1.026
Change in percent body fat  1.050 1.031 to 1.069
Change in waist-hip ratio 1st tertile 1 (reference) -
Change in waist-hip ratio 2nd tertile 1.161 1.048 to 1.287
Change in waist-hip ratio 3rd tertile 1.288 1.148 to 1.446
Model 2
a
Change in skeletal muscle index 0.972 0.953 to 0.991
Change in percent body fat  1.006 0.954 to 1.060
Change in waist-hip ratio 1st tertile 1 (reference) -
Change in waist-hip ratio 2nd tertile 1.118 1.005 to 1.244
Change in waist-hip ratio 3rd tertile 1.224 1.088 to 1.376
Change in HOMA β 0.987 0.987 to 0.988
Change in HOMA-IR 1st tertile 1 (reference) -
Change in HOMA-IR 2nd tertile 3.129 2.791 to 3.506
Change in HOMA-IR 3rd tertile 10.295 9.096 to 11.652
HOMA, homeostasis model assessment; OR, odds ratio; CI, confi-
dence interval; IR, insulin resistance.
aAdjusted for age, gender, fasting blood glucose, triglyceride, total 
cholesterol, systolic blood pressure and baseline weight.144
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es of SMI decreased from the 3rd to 1st tertiles (Fig. 2). For 
HOMA indices, the proportion of progressors increased as the 
changes of HOMA-IR increased from 1st to 3rd tertiles, and 
the proportion of progressors was significantly lower in 3rd 
tertile group, which demonstrated the smallest change in 
HOMA β-cell function compared with the 1st and 2nd tertiles 
(Fig. 2). These comparisons were all statistically significant 
(P<0.05).
DISCUSSION
In this study, our results indicated that increased weight gain 
was the significant predictor for glycemic progression in sub-
jects without diabetes mellitus at baseline during a four-year 
follow-up in an observational cohort without intentional in-
tervention. Among the components of body composition as-
sessed by the BIA method, increase in WHR was the strongest 
effector for future glycemic progression. However, when 
HOMA-IR was included in the same model, an increase in 
HOMA-IR predicted a higher risk for glycemic progression 
compared with increase in weight gain or WHR. HOMA β-cell 
function produced a negative correlation with glycemic pro-
gression. For the changes in each parameter in four years, 
changes in weight, percent body fat and WHR demonstrated a 
significant positive correlation with the proportion of progres-
sors. Although it was attenuated after adjustment for confound-
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ing factors, SMI demonstrated a significantly negative associa-
tion with glycemic progression. 
  In our study, during the four-year follow-up period in non-
diabetic participants in a regular health check-up program in 
a university hospital, compared with the subjects who lost 
more than 5% of their initial weight, subjects who gained more 
than 5% of their initial weight in four years showed 2.3-fold 
increased risk for glycemic progression, confirming the delete-
rious effects of weight gain on diabetes risk and glycemic pro-
gression, in line with the results from previous intervention 
studies. In addition, the mean percent weight change in all the 
participants in this study was relatively smaller than expected, 
about 0.89% in four years. In contrast with previous interven-
tion studies in which 5 to 7% weight change was used as the 
target for intervention [16,17], the results of our study could 
be interpreted in aspects relatively closer to the real-practice 
setting. As an observational study, only 9.5% of the partici-
pants lost 5% of their initial weight in four years without inter-
vention. In the recently published Look AHEAD (Action for 
Health in Diabetes) study performed in diabetes patients, while 
the lifestyle intervention group lost 8.6% of their initial weight 
at one year on average, the education control group showed 
only 0.7% weight loss [18]. From these results and our current 
study results this suggests that in the general adult population 
without any lifestyle intervention, the range of weight change 
is not great, and therefore, a very small change in weight could 
impact the metabolic status.
  In this study, an interval increase in HOMA-IR was the most 
significant predictor for glycemic progression compared with 
weight change or visceral obesity assessed by WHR. In the 
Mexico City study, in which HOMA indices were assessed in 
1,449 Mexican subjects without diabetes, after 3.5 years, the 
development of diabetes was associated with lower HOMA % 
sensitivity at baseline [19]. Although cross-sectional studies 
have been performed on the association of HOMA-indices 
with risk for diabetes or studies performed in subjects with 
type 2 diabetes [9,10], longitudinal studies assessing the asso-
ciation of baseline and the changes of HOMA indices with 
glycemic progression in a large number of Asian subjects are 
scarce. This study was the first study that assessed HOMA in-
dices longitudinally in a large number of Asian subjects and 
analyzed their association with glycemic progression in non-
diabetic subjects.    
  In addition to weight change, changes in body fat distribu-
tion may influence diabetes risk. It has been shown that a rela-
tively minor loss of body weight, which was accompanied by a 
major reduction in visceral fat mass and liver fat content, was 
associated with improved insulin sensitivity [20]. Visceral fat 
is known to be metabolically more active compared to non-
visceral adipose tissue and to be a major source for free fatty 
acids (FFA) and adipokine production [21,22]. Moreover, vis-
ceral fat perturbs metabolism by exposing the liver to a high 
concentration of FFAs, causing steatohepatitis and hepatic in-
sulin resistance. In Diabetes Prevention Program, decreased 
diabetes risk by lifestyle intervention was associated with re-
ductions in body weight, BMI, and central body fat distribu-
tion after adjustment for age and self-reported ethnicity [3]. In 
our study, increased abdominal obesity assessed by WHR and 
measured by BIA produced a significant linear association with 
increased glycemic progression in subjects with no history of 
diabetes. In contrast, percent body fat change had a weaker ef-
fect on glycemic progression when weight change and HOMA 
indices were included in the model, suggesting that it is not 
the simple increment of fat amount, but where the fat is depos-
ited, which carries more importance in glycemic progression.
  Age-related loss of skeletal muscle mass results in decreased 
skeletal muscle strength, and increased morbidity and mortal-
ity among the elderly [23,24]. Skeletal muscle is the main tar-
get for glucose use and insulin activity; therefore, this tissue 
may be important for glucose metabolism and could be an 
original target to treat metabolic disorders, such as insulin re-
sistance, impaired glucose tolerance and type 2 diabetes [25,26]. 
In a recent report from the Health, Aging, and Body Compo-
sition Study (Health ABC Study), older adults with type 2 dia-
betes exhibited excessive loss of appendicular lean mass and 
trunk fat mass compared with non-diabetic subjects [5]. In 
our study, subjects with a high baseline SMI and lower timely 
decrease in SMI (lean mass adjusted by weight), demonstrated 
reduced glycemic progression compared with the subjects with 
a higher decrease in SMI. Furthermore, the progressors showed 
a significantly larger decrease in SMI in four years of follow-up 
compared with non-progressors, although there was no differ-
ence between the baseline SMI values between those two 
groups, emphasizing the importance of changes in muscle 
mass in glycemic progression. However, this significance was 
attenuated when all the components of body composition 
were included in the same model, suggesting that other com-
ponents of body composition might be more important in 
glucose metabolism. Nonetheless, this study was to our knowl-
edge, the first study to report and compare the effect of muscle 146
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mass on glycemic progression in subjects without diabetes.
  This study has some limitations. First, diabetes development 
was not selected as the target end-point in the analyses. The 
reason that we chose glycemic progression as the primary end 
point, not the development of diabetes itself, was because the 
overall incidence of diabetes in this cohort during the four-year 
period of observation, was relatively low compared with other 
intervention studies [16,17]. The reason for the low incidence 
of diabetes could be due to ‘healthy worker effect’ in that the 
study participants who obeyed the company strategy and par-
ticipated in the regular exam might be mentally and physically 
healthier than those subjects that did not. Another reason 
could be the social status of the participants in our study co-
hort, in that most of the participants were either the employee 
or his or her family members of the large industrial companies 
that could afford the annual or biennial health check-up ex-
ams that the government recommends. Second, the diagnosis 
of diabetes mellitus or prediabetes was made by only one epi-
sode of high fasting glucose level or self-report of diabetes in 
the health check-up program, not oral glucose tolerance test 
(OGTT). However, in the studies managing large-scale health 
data, performing OGTT would be not feasible and not cost-
effective [27]. Third, the use of the BIA method, to analyze 
body composition, could have biased the results, as the accu-
racy of this method has been debated. However, for the analy-
sis of the body composition, BIA has been shown to have good 
correlation with dual-energy X-ray absorptiometry [28,29]. 
Fourth, personal history for medication, physical activity, 
smoking and alcohol drinking was not available for the analy-
ses. In particular, the absence of the effect of physical activity 
could have bias in the analyses. However, there is still debate 
on whether being fat or not fit is important on glycemic pro-
gression [30]. Despite the above mentioned limitations, this 
was the first large-scale study performed in an Asian popula-
tion to observe the effects of changes in weight and body com-
position on glycemic progression with the longitudinal assess-
ment of HOMA indices, during a four year follow-up period 
in subjects without history of diabetes.
  In conclusion, without intentional intervention, change in 
body weight, even in relatively narrow range of a four year pe-
riod of observation, conferred increased risk for glycemic pro-
gression to IFG or diabetes in adult subjects without a history 
of diabetes. Furthermore, increased HOMA-IR during the fol-
low-up period had the most significant predictive power for 
glycemic progression. Among the components of body com-
position, increase in abdominal obesity assessed by WHR 
demonstrated the most significant association with glycemic 
progression, although the influence was not bigger than in-
creased HOMA-IR. Changes in muscle mass showed a signifi-
cant positive correlation with glycemic progression, although 
these effects could not overcome the deleterious effects of in-
crease in visceral fat or HOMA-IR. These findings confirm 
that earlier intervention in lifestyle change to ultimately pre-
vent weight gain and insulin resistance might be the most ef-
fective way for the prevention of the worldwide epidemic of 
diabetes mellitus. 
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